Noroxin and Rash erythematous aggravated - a phase IV clinical study of FDA data

Summary:

Rash erythematous aggravated is reported as a side effect among people who take Noroxin (norfloxacin), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Ditropan, and have Breast cancer.

The phase IV clinical study analyzes which people have Rash erythematous aggravated when taking Noroxin. It is created by eHealthMe based on reports of 1,655 people who have side effects when taking Noroxin from the FDA, and is updated regularly.

What is Noroxin?

Noroxin has active ingredients of norfloxacin. It is often used in urinary tract infection. eHealthMe is studying from 1,675 Noroxin users. Check the latest studies of Noroxin.

What is Rash erythematous aggravated?

Rash erythematous aggravated (redness of the skin) is found to be associated with 1,391 drugs and 601 conditions by eHealthMe. Check the latest studies of Rash erythematous aggravated.

On Jul, 08, 2026

1,655 people reported to have side effects when taking Noroxin.
Among them, 18 people (1.09%) have Rash erythematous aggravated.

Could Noroxin cause Rash erythematous aggravated?

Among these 18 people:

How long have people been on Noroxin when they have Rash erythematous aggravated? *

What is the gender of people who have Rash erythematous aggravated when taking Noroxin? *

female: 72.22 %
male: 27.78 %

What is the age of people who have Rash erythematous aggravated when taking Noroxin? *

What are other drugs people take besides Noroxin? *

Zometa: 1 person, 5.56%
Zofran: 1 person, 5.56%
Aredia: 1 person, 5.56%
Arimidex: 1 person, 5.56%
Augmentin '125': 1 person, 5.56%
Carbamazepine: 1 person, 5.56%
Coumadin: 1 person, 5.56%
Cyclophosphamide: 1 person, 5.56%
Diltiazem Hydrochloride: 1 person, 5.56%
Ditropan: 1 person, 5.56%

What are other side effects people have besides Rash erythematous aggravated? *

Fever: 6 people, 33.33%
Drug Hypersensitivity: 4 people, 22.22%
Face Oedema (swelling of face): 4 people, 22.22%
Rashes (redness): 4 people, 22.22%
Itching: 4 people, 22.22%
Toxic Skin Eruption (skin breakdown due to toxic substance): 3 people, 16.67%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 16.67%
Henoch-Schonlein Purpura (inflammation of the blood vessels in the skin and other body organs): 2 people, 11.11%
Rash Pruritic (redness with itching): 2 people, 11.11%
Oedema Peripheral (superficial swelling): 2 people, 11.11%

What are the existing conditions these people have? *

Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 5.56%
Escherichia Urinary Tract Infection (urinary tract infection by escherichia coli): 1 person, 5.56%
Breast Cancer: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Noroxin and have Rash erythematous aggravated?

- Check whether Rash erythematous aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Noroxin:

Noroxin (1,675 reports)

Browse all side effects of Noroxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash erythematous aggravated:

Rash erythematous aggravated (1,391 drugs)

Browse all the conditions that are associated with Rash erythematous aggravated:

Rash erythematous aggravated (601 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on norfloxacin (the active ingredients of Noroxin) and Noroxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.